GFAP and Alzheimer disease: In addition, blood GFAP concentrations can also be used as an accessible biomarker for AD pathology (O’Connor et al., 2022), in the differential diagnosis of AD as well as the conversion of MCI-to-dementia in AD cohorts (Cicognola et al., 2021; Oeckl et al., 2022).